Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Paul Balk, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Available: 07/24/19, Expires: 07/31/21

The lab has a broad interest in further understanding the molecular basis of prostate cancer (PCa) development and progression in order to identify new therapies for prevention and treatment. The androgen receptor (AR) is required for PCa development, and the standard systemic treatment for PCa is androgen deprivation therapy to suppress AR function. However, patients invariably relapse and AR activity generally persists in these resistant tumors. Therefore, one focus is on molecular biology of AR and mechanisms driving its activity in patients who relapse despite AR targeted therapies. We also have projects related to SOX9, WNT signaling, and apoptotic pathways in PCa. Our studies employ cell line and mouse models, patient derived xenografts, and clinical samples from patients on clinical trials. Depending on experience, students would in most cases initially participate in an ongoing project in collaboration with a senior postdoctoral fellow or junior faculty member, and subsequently develop an aspect of the work into an independent project.


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA168393 (BALK, STEVEN P) May 13, 2014 - Apr 30, 2019
    NIH/NCI
    SOX9 Mediation of AR and ERG Driven Prostate Cancer
    Role: Principal Investigator
  2. P01CA163227 (BALK, STEVEN P) May 24, 2013 - Jan 31, 2024
    NIH/NCI
    Androgen Receptor Action in Castration Resistant Prostate Cancer
    Role: Principal Investigator
  3. R01CA111803 (BALK, STEVEN P.) May 1, 2007 - Mar 30, 2012
    NIH/NCI
    Targeting AR-NCoR Interaction in Prostate Cancer
    Role: Principal Investigator
  4. R21NS057051 (BALK, STEVEN P.) Jul 1, 2006 - Jun 30, 2008
    NIH/NINDS
    HTS for Androgen Receptor Antagonists that Recruit NCoR
    Role: Principal Investigator
  5. R01DK061047 (BALK, STEVEN P.) Jul 1, 2002 - May 31, 2007
    NIH/NIDDK
    AR Transgene Model of Prostate Intraepithelial Neoplasia
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Richters A, Doyle SK, Freeman DB, Lee C, Leifer BS, Jagannathan S, Kabinger F, Koren JV, Struntz NB, Urgiles J, Stagg RA, Curtin BH, Chatterjee D, Mathea S, Mikochik PJ, Hopkins TD, Gao H, Branch JR, Xin H, Westover L, Bignan GC, Rupnow BA, Karlin KL, Olson CM, Westbrook TF, Vacca J, Wilfong CM, Trotter BW, Saffran DC, Bischofberger N, Knapp S, Russo JW, Hickson I, Bischoff JR, Gottardis MM, Balk SP, Lin CY, Pop MS, Koehler AN. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2020 Oct 20. PMID: 33086052.
    Citations:    Fields:    
  2. Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk SP, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clin Cancer Res. 2020 Oct 09. PMID: 33037017.
    Citations:    Fields:    
  3. Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, Patalano S, Macoska JA, Corey E, Chen S, Balk SP, He HH, Cai C. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020 Oct; 52(10):1011-1017. PMID: 32868907.
    Citations:    Fields:    
  4. Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020 Aug 10; 38(2):279-296.e9. PMID: 32679108.
    Citations:    Fields:    
  5. Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk SP. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. Elife. 2020 Jun 02; 9. PMID: 32484436.
    Citations: 1     Fields:    
  6. Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, Kung J, Wu J, Corey E, Montgomery B, Mace S, Gianolio DA, Bubley GJ, Balk SP, Giannakakou P, Bhatt RS. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. J Clin Invest. 2020 Jun 01; 130(6):3287-3298. PMID: 32478682.
    Citations:    Fields:    
  7. Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100. PMID: 32127357.
    Citations: 1     Fields:    
  8. Russo JW, Nouri M, Balk SP. Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1. Cancer Discov. 2019 11; 9(11):1490-1492. PMID: 31676563.
    Citations:    Fields:    Translation:HumansCells
  9. Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precis Oncol. 2019; 3. PMID: 31528835.
    Citations: 2     
  10. Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai C. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. Cancer Res. 2019 10 15; 79(20):5260-5271. PMID: 31444154.
    Citations:    Fields:    Translation:HumansCells
  11. Patterson JC, Joughin BA, Prota AE, Mühlethaler T, Jonas OH, Whitman MA, Varmeh S, Chen S, Balk SP, Steinmetz MO, Lauffenburger DA, Yaffe MB. VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells. Cell Syst. 2019 07 24; 9(1):74-92.e8. PMID: 31302152.
    Citations: 4     Fields:    Translation:HumansCells
  12. Einstein DJ, Arai S, Balk SP. Targeting the androgen receptor and overcoming resistance in prostate cancer. Curr Opin Oncol. 2019 05; 31(3):175-182. PMID: 30893145.
    Citations: 1     Fields:    Translation:Humans
  13. Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EA. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019 12; 22(4):560-568. PMID: 30890759.
    Citations: 3     Fields:    Translation:Humans
  14. Poluben L, Bryke CR, Hsu Y, Shumeiko O, Neumerzhitska L, Klimuk B, Rybchenko L, Klymenko S, Balk SP, Fraenkel PG. Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis. Exp Oncol. 2019 Mar; 41(1):53-56. PMID: 30932413.
    Citations:    Fields:    Translation:Humans
  15. Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019 03 18; 35(3):401-413.e6. PMID: 30773341.
    Citations: 14     Fields:    Translation:HumansCells
  16. Russo JW, Balk SP. Initiation and Evolution of Early Onset Prostate Cancer. Cancer Cell. 2018 12 10; 34(6):874-876. PMID: 30537509.
    Citations: 2     Fields:    Translation:HumansCells
  17. Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019 01 02; 129(1):192-208. PMID: 30334814.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  18. Poluben L, Puligandla M, Neuberg D, Bryke CR, Hsu Y, Shumeiko O, Yuan X, Voznesensky O, Pihan G, Adam M, Fraenkel E, Rasnic R, Linial M, Klymenko S, Balk SP, Fraenkel PG. Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. Am J Hematol. 2019 01; 94(1):62-73. PMID: 30295334.
    Citations: 3     Fields:    Translation:Humans
  19. Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018 11 15; 78(22):6354-6362. PMID: 30242112.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  20. Russo JW, Liu X, Ye H, Calagua C, Chen S, Voznesensky O, Condulis J, Ma F, Taplin ME, Einstein DJ, Balk SP, Chen S. Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018 12 01; 438:97-104. PMID: 30217568.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  21. Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 01 01; 25(1):426-439. PMID: 30181386.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  22. Kolodny G, Li X, Balk S. Addressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries. Bioessays. 2018 10; 40(10):e1800057. PMID: 30101540.
    Citations:    Fields:    Translation:Humans
  23. Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res. 2018 11 01; 24(21):5458-5470. PMID: 30021909.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  24. Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res. 2018 09 15; 78(18):5203-5215. PMID: 30012673.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  25. Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 08 15; 78(16):4716-4730. PMID: 29921690.
    Citations: 7     Fields:    Translation:Humans
  26. Xu X, Balk SP, Isaacs WB, Ma J. Calcium signaling: an underlying link between cardiac disease and carcinogenesis. Cell Biosci. 2018; 8:39. PMID: 29930797.
    Citations: 1     
  27. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 05; 73(5):715-723. PMID: 29258679.
    Citations: 18     Fields:    Translation:Humans
  28. Han GC, Hwang J, Wankowicz SAM, Zhang Z, Liu D, Cibulskis C, Gaviola GC, Ghazikhanian V, McKay RR, Bubley GJ, Carter SL, Balk SP, Hahn WC, Taplin ME, Van Allen EM. Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1. PMID: 32913968.
    Citations:    
  29. Exley MA, Wilson SB, Balk SP. Isolation and Functional Use of Human NKT Cells. Curr Protoc Immunol. 2017 Nov 01; 119:14.11.1-14.11.20. PMID: 29091262.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  30. Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res. 2017 Nov 15; 23(22):6812-6822. PMID: 28893901.
    Citations: 8     Fields:    Translation:HumansCells
  31. Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. Endocr Relat Cancer. 2017 08; 24(8):393-404. PMID: 28663228.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  32. Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP. Positive feedback loop mediated by protein phosphatase 1a mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 2017 04 20; 45(7):3738-3751. PMID: 28062857.
    Citations: 6     Fields:    Translation:HumansCells
  33. Bubley GJ, Balk SP. Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. J Clin Oncol. 2017 07 01; 35(19):2103-2105. PMID: 28414609.
    Citations: 3     Fields:    Translation:HumansCells
  34. Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB. Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4592-4601. PMID: 28389510.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  35. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017 07; 7(7):750-765. PMID: 28274958.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  36. Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res. 2017 Jul 15; 23(14):3510-3519. PMID: 28193627.
    Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
  37. DeLeonardis K, Sedgwick K, Voznesensky O, Matloff E, Hofstatter E, Balk S, Tung N. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients. Breast J. 2017 Jul; 23(4):461-464. PMID: 28139868.
    Citations: 3     Fields:    Translation:Humans
  38. Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP. Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res. 2017 Jul 15; 23(14):3823-3833. PMID: 28119368.
    Citations: 9     Fields:    Translation:HumansCells
  39. Kelly K, Balk SP. Reprogramming to resist. Science. 2017 01 06; 355(6320):29-30. PMID: 28059730.
    Citations: 4     Fields:    Translation:HumansCells
  40. Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176. PMID: 28151719.
    Citations: 12     Fields:    Translation:Humans
  41. Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep. 2016 10 18; 17(4):966-976. PMID: 27760327.
    Citations: 17     Fields:    Translation:HumansCells
  42. McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945. PMID: 27683182.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  43. Gerrin SJ, Sowalsky AG, Balk SP, Ye H. Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate. 2016 09; 76(13):1227-36. PMID: 27272561.
    Citations: 2     Fields:    Translation:Humans
  44. Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016 05 26; 533(7604):547-51. PMID: 27225130.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  45. Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016 05 02; 126(5):1745-58. PMID: 27043282.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  46. Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82. PMID: 26936914.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  47. Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen S. Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. 2016 Jan 12; 7(2):1754-64. PMID: 26636645.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  48. Taplin ME, Balk SP. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer? JAMA Oncol. 2015 Aug; 1(5):577-9. PMID: 26181796.
    Citations:    Fields:    Translation:HumansCells
  49. Sowalsky AG, Sager R, Schaefer RJ, Bratslavsky G, Pandolfi PP, Balk SP, Kotula L. Loss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget. 2015 May 20; 6(14):12383-91. PMID: 25906751.
    Citations: 5     Fields:    Translation:Humans
  50. Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8. PMID: 25808865.
    Citations: 19     Fields:    Translation:AnimalsCells
  51. Plymate SR, Bhatt RS, Balk SP. Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2. Cancer Cell. 2015 Feb 09; 27(2):158-9. PMID: 25670076.
    Citations: 6     Fields:    Translation:HumansAnimals
  52. Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015 Jun 05; 234:332-8. PMID: 25514466.
    Citations: 19     Fields:    Translation:Humans
  53. Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, Wang Y, Metzger E, Schüle R, Liu XS, Brown M, Balk SP. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014 Dec 11; 9(5):1618-1627. PMID: 25482560.
    Citations: 40     Fields:    Translation:HumansCells
  54. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80. PMID: 25320358.
    Citations: 57     Fields:    Translation:HumansCells
  55. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15. PMID: 25311217.
    Citations: 55     Fields:    Translation:HumansCTClinical Trials
  56. Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li W. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res. 2015 Jan; 13(1):98-106. PMID: 25189356.
    Citations: 28     Fields:    Translation:HumansCells
  57. Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJ. The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol. 2015 Feb; 193(2):690-8. PMID: 25132238.
    Citations: 21     Fields:    Translation:HumansCells
  58. McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):325-31. PMID: 25091040.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  59. Porcelli S, Yockey CE, Brenner MB, Balk SP. Pillars article: analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- a/ß T cells demonstrates preferential use of several Vß genes and an invariant TCR a chain. J. Exp. Med. 1993. 178: 1-16. J Immunol. 2014 Aug 01; 193(3):977-92. PMID: 25049428.
    Citations:    Fields:    Translation:HumansAnimalsCells
  60. Balk SP. Androgen receptor functions in prostate cancer development and progression. Asian J Androl. 2014 Jul-Aug; 16(4):561-4. PMID: 24759584.
    Citations: 4     Fields:    Translation:HumansCells
  61. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014 Aug 01; 20(15):4075-85. PMID: 24874833.
    Citations: 37     Fields:    Translation:HumansCells
  62. Chin YR, Yuan X, Balk SP, Toker A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014 Aug; 4(8):942-55. PMID: 24838891.
    Citations: 32     Fields:    Translation:HumansCells
  63. Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CJ, Lee GS, Chen S, Balk SP, Liu XS, Brown M, Kantoff PW. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7319-24. PMID: 24778216.
    Citations: 94     Fields:    Translation:HumansAnimalsCells
  64. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014 Mar 15; 20(6):1590-600. PMID: 24449822.
    Citations: 71     Fields:    Translation:HumansAnimalsCells
  65. Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37. PMID: 24323034.
    Citations: 27     Fields:    Translation:HumansCells
  66. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014 Apr; 40(3):426-33. PMID: 24139549.
    Citations: 46     Fields:    Translation:Humans
  67. Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Transl Androl Urol. 2013 Sep 01; 2(3):148-157. PMID: 25580383.
    Citations: 9     
  68. Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TM. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol. 2013 Nov; 138:281-9. PMID: 23851165.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  69. Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff PW. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014 May 22; 33(21):2790-800. PMID: 23770851.
    Citations: 39     Fields:    Translation:HumansCells
  70. Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014 May 29; 33(22):2815-25. PMID: 23752196.
    Citations: 111     Fields:    Translation:HumansAnimalsCells
  71. Chen S, Jiang X, Gewinner CA, Asara JM, Simon NI, Cai C, Cantley LC, Balk SP. Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal. 2013 May 28; 6(277):ra40. PMID: 23716717.
    Citations: 13     Fields:    Translation:AnimalsCells
  72. Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013 Jul 19; 8(7):1423-8. PMID: 23594111.
    Citations: 14     Fields:    Translation:HumansCells
  73. Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar; 123(3):1109-22. PMID: 23426182.
    Citations: 59     Fields:    Translation:HumansAnimalsCells
  74. Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL, Yuan X. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/ß-catenin activation in breast cancer. J Biol Chem. 2013 Mar 01; 288(9):6478-87. PMID: 23306204.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  75. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14; 338(6113):1465-9. PMID: 23239736.
    Citations: 272     Fields:    Translation:HumansAnimalsCells
  76. Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res. 2013 Feb 01; 73(3):1050-5. PMID: 23204237.
    Citations: 33     Fields:    Translation:Humans
  77. Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol. 2012 Nov; 26(11):1836-46. PMID: 23023563.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  78. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, Balk SP, O'Shea D, O'Farrelly C, Exley MA. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity. 2012 Sep 21; 37(3):574-87. PMID: 22981538.
    Citations: 166     Fields:    Translation:HumansAnimalsCells
  79. Wang H, Xu Y, Fang Z, Chen S, Balk SP, Yuan X. Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation. PLoS One. 2012; 7(7):e41330. PMID: 22844460.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  80. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem. 2012 Mar 09; 287(11):8571-83. PMID: 22275373.
    Citations: 42     Fields:    Translation:HumansCells
  81. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J Biol Chem. 2012 Jan 13; 287(3):2090-8. PMID: 22139837.
    Citations: 24     Fields:    Translation:AnimalsCells
  82. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GM, Kantoff PW. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 01; 72(10):1093-103. PMID: 22127852.
    Citations: 44     Fields:    Translation:HumansCells
  83. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011 Oct 18; 20(4):457-71. PMID: 22014572.
    Citations: 160     Fields:    Translation:HumansCells
  84. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011 Oct; 18(5):R175-82. PMID: 21712345.
    Citations: 47     Fields:    Translation:Humans
  85. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011 Oct 15; 71(20):6503-13. PMID: 21868758.
    Citations: 148     Fields:    Translation:HumansAnimalsCells
  86. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73. PMID: 21606417.
    Citations: 54     Fields:    Translation:Humans
  87. Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SP. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol. 2011 Aug; 140(2):184-95. PMID: 21646050.
    Citations: 22     Fields:    Translation:HumansCells
  88. Exley MA, Wilson B, Balk SP. Isolation and functional use of human NKT cells. Curr Protoc Immunol. 2010 Aug; Chapter 14:Unit 14.11. PMID: 20814940.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  89. Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with a-galactosylceramide. PLoS One. 2010 Jun 25; 5(6):e11311. PMID: 20593019.
    Citations: 26     Fields:    Translation:AnimalsCells
  90. Porcelli S, Brenner MB, Greenstein JL, Terhorst C, Balk SP, Bleicher PA. Recognition of Cluster of Differentiation 1 Antigens by Human CD4-CD8- CytolyticT Lymphocyte. Nature. 1989. 341: 447-450. 1989. J Immunol. 2010 Apr 01; 184(7):3306-9. PMID: 20304831.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  91. Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 2010 May 14; 285(20):14980-9. PMID: 20231295.
    Citations: 36     Fields:    Translation:HumansCells
  92. Nowak M, Lynch L, Yue S, Ohta A, Sitkovsky M, Balk SP, Exley MA. The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol. 2010 Mar; 40(3):682-7. PMID: 20039304.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  93. Yue SC, Nowak M, Shaulov-Kask A, Wang R, Yue D, Balk SP, Exley MA. Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol. 2010 Jan 01; 184(1):268-76. PMID: 19949077.
    Citations: 10     Fields:    Translation:AnimalsCells
  94. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. PMID: 19887483.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  95. Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2. PMID: 19815488.
    Citations: 8     Fields:    Translation:Humans
  96. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology. 2009 Nov; 74(5):1156-61. PMID: 19647299.
    Citations: 8     Fields:    Translation:Humans
  97. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23; 138(2):245-56. PMID: 19632176.
    Citations: 398     Fields:    Translation:HumansCells
  98. Chen S, Kesler CT, Paschal BM, Balk SP. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem. 2009 Sep 18; 284(38):25576-84. PMID: 19622840.
    Citations: 35     Fields:    Translation:HumansCells
  99. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009 Aug 01; 69(15):6027-32. PMID: 19584279.
    Citations: 69     Fields:    Translation:HumansAnimalsCells
  100. Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009 Jun 15; 69(12):5202-9. PMID: 19491261.
    Citations: 23     Fields:    Translation:HumansCells
  101. Shen HC, Balk SP. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell. 2009 Jun 02; 15(6):461-3. PMID: 19477425.
    Citations: 10     Fields:    Translation:HumansCells
  102. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009 Apr 15; 69(8):3356-63. PMID: 19351832.
    Citations: 97     Fields:    Translation:HumansCells
  103. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol. 2009 Jan-Feb; 27(1):36-41. PMID: 19111796.
    Citations: 94     Fields:    Translation:HumansAnimalsCells
  104. Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62. PMID: 18980990.
    Citations: 23     Fields:    Translation:HumansCells
  105. Kaur R, Yuan X, Lu ML, Balk SP. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate. 2008 Oct 01; 68(14):1510-6. PMID: 18642328.
    Citations: 35     Fields:    Translation:HumansCells
  106. Hodgson MC, Shen HC, Hollenberg AN, Balk SP. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. . 2008 Oct; 7(10):3187-94. PMID: 18852122.
    Citations: 20     Translation:HumansAnimalsCells
  107. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NS. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett. 2008 Nov 15; 18(22):5916-9. PMID: 18667312.
    Citations: 13     Fields:    Translation:AnimalsCells
  108. van der Vliet HJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MA. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol. 2008 Jun 01; 180(11):7287-93. PMID: 18490728.
    Citations: 14     Fields:    Translation:HumansCells
  109. Exley MA, Hou R, Shaulov A, Tonti E, Dellabona P, Casorati G, Akbari O, Akman HO, Greenfield EA, Gumperz JE, Boyson JE, Balk SP, Wilson SB. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol. 2008 Jun; 38(6):1756-66. PMID: 18493987.
    Citations: 41     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  110. Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee GS. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate. 2008 Jun 01; 68(8):839-48. PMID: 18302198.
    Citations: 23     Fields:    Translation:HumansCells
  111. Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bubley G, Oh WK, Kantoff PW, Balk SP. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068. PMID: 27948754.
    Citations:    
  112. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9. PMID: 18399827.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  113. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63. PMID: 18394010.
    Citations: 8     Fields:    Translation:HumansCells
  114. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP, Yuan X. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008 Mar 15; 68(6):1625-30. PMID: 18339840.
    Citations: 79     Fields:    Translation:HumansAnimalsCells
  115. Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol. 2008 Apr; 36(4):464-72. PMID: 18261838.
    Citations: 12     Fields:    Translation:HumansCells
  116. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008 Feb 01; 6:e001. PMID: 18301781.
    Citations: 133     Fields:    Translation:HumansCells
  117. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007 Dec; 14(4):995-1005. PMID: 18045951.
    Citations: 22     Fields: